How well does Biktarvy work for people in difficult situations in France?
Part of Infections clinical trials.
This study looks at how well the HIV medication Biktarvy works in real life for people in France who are in difficult financial or social situations. It includes people who are starting Biktarvy for the first time or switching to it as a second treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and living with HIV.
- You have C2S or AME health insurance (special French programs for people in difficult situations).
- You are either starting HIV treatment for the first time with Biktarvy, or switching to Biktarvy as your second treatment (and your virus is either undetectable or not).
- You have had at least one follow-up doctor visit after starting or switching to Biktarvy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
This study measures the “hidden” HIV reservoir in the body and how it relates to blood levels of antiretroviral medicines. It may help doctors better understand why HIV can remain even when the virus is controlled.
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
This study tests a faster way to switch to a modern HIV medication (Biktarvy) in people who have recently moved to Quebec and are already on HIV treatment. The goal is to see if this quick switch helps keep the virus under control with fewer clinic visits.
This trial checks if the once-daily HIV pill Biktarvy (B/F/TAF) stays safe and works well for women who are newly pregnant (up to 12 weeks). It is for women already taking Biktarvy with a controlled virus load.
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.